Navigation Links
Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Date:1/25/2008

FRAZER, Pa., Jan. 25 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain. In addition, the FDA notified the Company that it will convene an advisory committee panel on May 6, 2008, to consider this application.

"We are pleased that the FENTORA application remains on schedule with an FDA action date of September 13, 2008," said Dr. Lesley Russell, Executive Vice President, Worldwide Medical and Regulatory Operations. "FENTORA is the first medication that has been evaluated in controlled clinical trials for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Therefore, it is not surprising that the agency decided to convene a panel to consider data on the use of FENTORA beyond the initial indication for breakthrough pain in cancer patients."

Included in the FENTORA sNDA are data from three randomized, placebo- controlled clinical trials and one long-term open-label safety study; including data from opioid-tolerant patients with chronic low back and neuropathic pain. The sNDA provides an evaluation of the onset of pain relief from 10 minutes to two hours, and has information regarding bioequivalence data for two routes of administration.

In 2006, FENTORA and an accompanying Risk Minimization Action Plan (RiskMAP) were approved by the FDA only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. The company developed and maintains a FENTORA RiskMAP to address the appropriate patient selection, dosing and administration of the medication.

About Cephalon, Inc.

Cephalon, Inc. is an international biop
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. CardioDynamics Provides 2007 Shareholder Meeting Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 Yuma Regional ... and complementary therapies brings comprehensive cancer care to ... Yuma Regional Cancer Center has officially opened. A ... program includes services such as open, semi-private and ... American Cancer Society Resource Center, hematology, rehabilitation center, ...
(Date:7/30/2014)... Md. , July 30, 2014 ... components to interrogate biology, but such devices can ... As such, researchers have looked ... in vitro metabolic engineering to characterize ... a chip. New devices are envisioned to recreate ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
Breaking Biology Technology:Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... than a Thousand Submissions Already Received for the ... USCAMBRIDGE, Mass., Jan. 15 The Nano Science ... and Sustainable Industries Organization (CTSI), today announced that ... the largest Cleantechnology, Biotechnology and Nanotechnology event in ...
... 15 The Court of ... found Boston Scientific Corporation,s Ding patent invalid, and reversed ... Coronary Stent infringed that patent. Cordis is very pleased ... rendered in July 2005 in Wilmington, Delaware. The ...
... have entered into a research collaboration to improve insect control in ... ... Research Triangle Park, NC (Vocus) January 15, 2009 -– DuPont and ... improve insect control in corn and soybeans. Under the agreement, ...
Cached Biology Technology:TechConnect World 2009 Announces January 28th 'Last Call' for Speaker-Proposals 2TechConnect World 2009 Announces January 28th 'Last Call' for Speaker-Proposals 3DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 2DuPont and Athenix Collaborate to Advance Insect Control in Corn, Soybeans 3
(Date:7/30/2014)... Chemical Society (ACS) announced today that David L. Kaplan, ... Biomaterials Science & Engineering as editor-in-chief. With the ... new journal will feature high-quality research in the rapidly ... naturally derived materials that interact with living or biological ... reflects the tremendous growth in the field of biomaterials ...
(Date:7/30/2014)... Institute (SALSI), a joint venture between The University of ... Texas Health Science Center at San Antonio, has selected ... winners, Emily Boice from UTSA and Lei Huang from ... project titled, "Novel engineered ferritins for tracking and protecting ... Huang,s research is focused on finding a treatment for ...
(Date:7/30/2014)... HIV infection could be as simple as inserting a ... University of Washington bioengineers have discovered a potentially faster ... from contracting HIV. Their method spins the drug into ... moisture, releasing higher doses of the drug than possible ... , "This could offer women a potentially more effective, ...
Breaking Biology News(10 mins):ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3
... release is available in Spanish . ... acids and they play a fundamental role in all of ... they, therefore, carry out numerous functions in an organism: immunological ... (they form part of enzymes) and a long list of ...
... hold promise for improved early disease screening, cancer staging, therapeutic ... Ge Wang , director of Virginia Tech,s Center for ... the refereed journal PLOS ONE . , ... framework "is a new way of thinking in the biomedical ...
... prepping for a hurricane, the bacterium Bacillus subtilis ... times. In a new study, scientists at Rice University and ... B. subtilis to begin preparing for survival, even ... down" and withdraw into a hardened spore. The new ...
Cached Biology News:Using computational biology for the annotation of proteins 2Using computational biology for the annotation of proteins 3Scanning innovation can improve personalized medicine 2Scanning innovation can improve personalized medicine 3Deciphering bacterial doomsday decisions 2Deciphering bacterial doomsday decisions 3
...
... Kit is an advanced system for isolating DNA from ... be used directly for any downstream application. ... to use in 56 minutes Low melting point ... and TBE gels No specialised equipment required ...
... Spin Columns provide a rapid and simple method ... bp to 10 kb) from stained agarose gels ... excised from an agarose gel and loaded into ... the column are a series of membranes and ...
... Kit has been designed for recovery of DNA from ... Features Ultra fast protocol: DNA is ready ... are easy to resuspend Bead uniformity prevents shearing ... (suitable for PCR) DNA is eluted into sterile ...
Biology Products: